P-21 (P021): Research Overview, Mechanism & Published Studies

P-21 (P021): Research Overview, Mechanism & Published Studies

Research Library entry. Updated August 2026.

Introduction to P-21 peptide research

P-21, generally published as P021 or Peptide 021, is a synthetic, CNTF-derived peptidergic research compound. It was developed from a short biologically active region of human ciliary neurotrophic factor (CNTF), a member of the interleukin-6 family of neuropoietic cytokines. CNTF has long been studied for roles in neuronal differentiation, survival, and neural progenitor biology. The P021 program used epitope mapping to reduce this biology to a compact peptide-based mimetic and then added a terminal adamantylated glycine modification intended to alter stability and central exposure characteristics.

Published P-21 peptide research is predominantly preclinical. The literature includes neuronal-cell experiments and studies in mice and rats, with particular attention to dentate-gyrus neurogenesis, synaptic markers, learning and memory tasks, and pathology measures in transgenic or aging models. Several reports frame P021 as a neurotrophic or neurogenic compound, but those terms describe the experimental hypotheses and endpoints used in those models; they do not establish a human therapeutic effect.

Nomenclature can cause confusion. In this article, P-21 and P021 refer to Peptide 021, not to the unrelated cell-cycle protein p21/CDKN1A. P021 is also distinct from full-length CNTF and from the longer CNTF-derived peptide P6 described in earlier work. This overview summarizes the published evidence relevant to P-21 peptide research and its proposed mechanisms. It is not a protocol, a dosing guide, or medical advice.

P-21 mechanism of action: CNTF-derived signaling, LIF, and BDNF

The proposed P-21 mechanism of action emerged from studies of CNTF and leukemia inhibitory factor (LIF) in neural progenitor systems. Native CNTF signals through a receptor complex comprising CNTF receptor alpha, LIF receptor beta, and gp130, with downstream JAK/STAT signaling. CNTF and LIF share portions of this receptor biology, and both participate in the regulation of neural-cell proliferation and differentiation. P021 is not full-length CNTF, and the available work does not establish that it reproduces all CNTF receptor interactions or all actions of the native cytokine.

In the authors’ preclinical model, P021 was reported to competitively inhibit LIF-associated signaling. This was associated with reduced STAT3 phosphorylation and with increased transcription and expression of brain-derived neurotrophic factor (BDNF). BDNF is relevant to neuronal survival, dendritic growth, synaptic plasticity, and the maturation and integration of adult-born hippocampal neurons. P021’s proposed downstream pathway is therefore indirect: altered LIF/STAT3 signaling is hypothesized to increase BDNF, which can engage TrkB-linked PI3K–AKT and ERK signaling.

One frequently discussed biochemical consequence concerns glycogen synthase kinase-3 beta (GSK-3β). In the 3xTg-AD mouse literature, P021-associated increases in BDNF/TrkB/AKT signaling were accompanied by increased inhibitory phosphorylation of GSK-3β and lower measures of abnormal tau phosphorylation. This is a mechanistic interpretation within a specific transgenic model, not evidence of a clinical mechanism in humans. The 2024 work of Mottolese and colleagues also provides an important qualification: P021 restored proliferation, survival, and maturation measures in a human cellular model of CDKL5 deficiency, but chronic exposure did not increase BDNF or substantially improve neuroanatomical deficits in the corresponding knockout-mouse model. The results underscore that pathway effects can be model- and context-dependent.

Published P-21 research summary

Neurogenesis and neuroplasticity research

Li et al. (2010), FEBS Letters. In a foundational mouse study, Li and colleagues compared CNTF-derived peptides incorporating adamantane and identified P021 as a short compound with neurotrophic activity in the tested models. The investigators reported increases in markers of dentate-gyrus neurogenesis and synaptic plasticity, alongside improved performance in mouse learning and memory assays. The study established the structural rationale for coupling the CNTF-derived sequence to adamantylated glycine and positioned P021 for subsequent preclinical work.

Chohan et al. (2011), Neurobiology of Aging. This study examined dentate-gyrus neurogenesis, dendritic and synaptic plasticity, and memory in animal models. The authors reported that the CNTF-derived neurotrophic peptide increased measures associated with progenitor proliferation and neuronal differentiation, as well as dendritic and synaptic endpoints. These findings are central to the P-21 neurogenesis hypothesis, while still being limited to the experimental systems studied.

Bolognin et al. (2014), Neurobiology of Aging. In aged Fischer rats, chronic P021 exposure was associated with reversal of age-associated deficits in neurogenesis and neuronal-plasticity measures. The study also included cognitive tasks and reported group differences favoring the P021-treated animals. As with all behavioral results, interpretation depends on the particular species, age, task design, and comparator conditions; it does not provide an inference about human cognitive outcomes.

Cognitive function, memory, and learning studies

Learning and memory outcomes have been recurring endpoints in P021 research because the dentate gyrus and hippocampal circuitry contribute to spatial and associative tasks in rodents. The original Li et al. work used mouse behavioral testing in conjunction with cellular and molecular measures. Bolognin et al. extended this line to an aging-rat paradigm, whereas later transgenic-mouse studies combined behavioral tasks with neuropathological measures.

Baazaoui and Iqbal (2017), Alzheimer’s Research & Therapy. Female 3xTg-AD mice received P021-containing diet or vehicle beginning before overt amyloid-beta and tau pathology, and were later evaluated with Morris water-maze and novel-object-location tasks. Relative to vehicle-treated transgenic controls, P021-treated mice showed reported improvements in the task measures and changes in dentate-gyrus neurogenesis and selected dendritic/synaptic markers. The study assessed a triple-transgenic mouse model; it did not test people with Alzheimer’s disease.

Kazim et al. (2017), Scientific Reports. In Ts65Dn mice, an established model used in Down-syndrome research, the authors reported that P021 exposure during prenatal to early postnatal development rescued developmental-delay measures in pups and later hippocampus-dependent memory measures in adult mice. The findings are informative for developmental timing in that model but should not be generalized beyond it.

Alzheimer’s disease model research

Several P021 studies used the 3xTg-AD model, which carries human APP, presenilin-1, and tau mutations and develops age-dependent amyloid and tau-related changes. These are model-specific experiments, not clinical trials and not evidence that P021 prevents or treats Alzheimer’s disease in people.

Kazim et al. (2014), Neurobiology of Disease. In 3xTg-AD mice, chronic oral P021 treatment was reported to attenuate measures of abnormal tau phosphorylation more robustly than amyloid-beta pathology, while also improving cognitive test outcomes in the study. The authors linked the observations to BDNF-associated signaling and inhibition of GSK-3β. This report is a key source for the proposed P-21/BDNF/GSK-3β model, but causal pathway assignment in vivo remains an area for additional investigation.

Baazaoui and Iqbal (2017), Journal of Alzheimer’s Disease. A related study examined amyloid-beta and tau pathology, as well as neuroinflammation-associated measures, in 3xTg-AD mice. The authors reported lower pathological-marker measures in their P021 group. In interpreting these findings, it is important to distinguish pathological readouts in a transgenic model from clinical disease-modification claims.

Wei et al. (2020), Alzheimer’s Research & Therapy. Researchers administered P021 during the prenatal-to-early-postnatal period in 3xTg-AD mice. At the reported follow-up time points, the P021 group showed better performance on measured cognitive tasks, lower tau hyperphosphorylation/accumulation at examined sites, and lower amyloid-plaque burden at a later time point. This work investigates an early-life experimental intervention in a genetically engineered mouse line; it provides no human developmental or clinical guidance.

Wei et al. (2021), Journal of Alzheimer’s Disease. A postnatal-treatment study in the same broad research area reported increased pCREB and BDNF expression and differences in synaptic and behavioral endpoints in the 3xTg-AD model. Together, the 2020 and 2021 reports test a developmental-window hypothesis in mice. Replication across independent laboratories and translation to humans have not been established.

Neuroinflammation and retinal research

Neuroinflammation-associated endpoints are also represented in the P021 literature. In the 3xTg-AD work, investigators measured microglial and astroglial markers alongside synaptic, tau, and amyloid-related measures. Reported changes are compatible with an altered inflammatory environment in the experimental model, but they do not identify a direct anti-inflammatory target for P021 or establish an effect in human neuroinflammatory conditions.

Liu et al. (2019), Frontiers in Aging Neuroscience. This study evaluated aged Fischer rats and aged 3xTg-AD mice for retinal changes described as AMD-like. Following chronic P021 exposure, the investigators reported differences in retinal-layer morphology, retinal pigment epithelium and Bruch’s-membrane features, and Iba-1/GFAP-associated microgliosis and astrogliosis measures. The authors noted design limitations, including the absence of a P021-treated wild-type mouse group in that portion of the experiment. These data broaden P021 research to retinal tissues but remain preclinical observations in rodent models.

Pharmacological profile and molecular information

P021 is commonly represented as Ac-DGGLAG-NH₂, with a reported molecular weight of approximately 578.3 Da. Descriptions sometimes call it a tetrapeptide because the CNTF-derived core corresponds to residues 148–151 of CNTF; chemically, the final P021 construct includes the added adamantylated glycine and is described in primary reports as a pentapeptide derivative. The N-terminus is acetylated and the C-terminus is amidated. The adamantane-containing terminal modification was incorporated to increase lipophilicity and reduce susceptibility to C-terminal exopeptidase degradation.

Preclinical reports describe P021 as blood–brain-barrier permeable and report stability in artificial gastric and intestinal fluids and plasma. In the Baazaoui and Iqbal 2017 report, P021 showed greater than 95% stability in artificial gastric juice over 30 minutes, approximately complete stability in intestinal fluid over 120 minutes, and plasma stability exceeding three hours. These values are experimental observations under stated assay conditions, not human pharmacokinetic parameters. Published animal studies have evaluated dietary, oral-gavage, and parenteral research delivery routes; the heterogeneity of routes and models makes them unsuitable for extrapolation into a product-use instruction.

Safety considerations in research

The published P021 safety record is limited. Rodent studies frequently report no obvious adverse observations, and some reports tracked body weight, food consumption, or general condition without identifying a treatment-related signal in their study conditions. Such observations are not a substitute for formal toxicology, reproductive toxicology, immunogenicity, interaction, long-term safety, or human pharmacokinetic studies.

There are no published, peer-reviewed human clinical trials establishing P021 safety, tolerability, pharmacokinetics, or efficacy. The small size and CNTF-derived design of P021 should not be used to infer human safety. Further, the 2024 CDKL5 study shows that not all preclinical models yield the same biological response. Researchers interpreting this literature should account for model dependence, limited sample sizes in some experiments, sex and age restrictions, treatment timing, route/formulation differences, and the concentration of much of the evidence within related research groups.

Current research status

P021 remains a preclinical research compound. Its published literature is concentrated in cell culture and rodent work rather than human studies. The central questions are mechanistic and translational: whether the reported LIF/STAT3–BDNF association can be independently reproduced, which cell types and receptor systems are necessary, how reproducible the behavioral and pathology findings are across models, and whether adequate safety and exposure data can be developed for any future clinical investigation.

The more recent human-cell/knockout-mouse CDKL5 study is particularly useful because it reports both positive cellular results and limited in vivo effects in the mouse model. That mixed result is a reminder that P-21 peptide research should be read as a developing preclinical evidence base rather than as a settled account of a single mechanism or outcome.

P-21 compared with CNTF

CNTF is a full-length endogenous cytokine-like neurotrophic factor with broad receptor-mediated biology and a substantially larger protein structure. P021 is a short synthetic derivative modeled on a small CNTF region, modified with adamantylated glycine. The design rationale was to retain selected activity observed for the parent sequence while producing a smaller compound with improved experimental stability and central exposure characteristics.

That relationship does not make P021 interchangeable with CNTF. Full-length CNTF signals through a defined multi-component receptor complex and has pleiotropic systemic actions. P021’s reported effects are inferred largely from downstream observations—especially LIF/STAT3, BDNF, AKT, and GSK-3β measures—rather than from a complete receptor-binding and selectivity map. Native CNTF also has pharmacokinetic and systemic-tolerability limitations noted in its own literature; P021 was engineered in response to those limitations, but direct comparative human safety or efficacy data are not available.

References

1. Li B, Wanka L, Blanchard J, Liu F, Chohan MO, Iqbal K, Grundke-Iqbal I. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Letters. 2010;584(15):3359–3365. doi:10.1016/j.febslet.2010.06.025.
2. Chohan MO, Li B, Blanchard J, Tung YC, Heaney AT, Rabe A, Iqbal K, Grundke-Iqbal I. Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. Neurobiology of Aging. 2011;32(8):1420–1434.
3. Bolognin S, Buffelli M, Puoliväli J, Iqbal K. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiology of Aging. 2014;35(9):2134–2146. doi:10.1016/j.neurobiolaging.2014.02.017.
4. Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, Iqbal K. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer’s disease. Neurobiology of Disease. 2014;71:110–130. PMID:25046994.
5. Kazim SF, Iqbal K. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease. Molecular Neurodegeneration. 2016;11:50. doi:10.1186/s13024-016-0119-y. PMID:27400746.
6. Baazaoui N, Iqbal K. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimer’s Research & Therapy. 2017;9:45. doi:10.1186/s13195-017-0273-7. PMID:28655344.
7. Kazim SF, Blanchard J, Bianchi R, Iqbal K. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn Down syndrome mouse model. Scientific Reports. 2017;7:45561. doi:10.1038/srep45561. PMID:28368015.
8. Baazaoui N, Iqbal K. Prevention of amyloid-β and tau pathologies, associated neurodegeneration, and cognitive deficit by early treatment with a neurotrophic compound. Journal of Alzheimer’s Disease. 2017;58(2):559–573. doi:10.3233/JAD-170075. PMID:28387677.
9. Liu Y, Wei W, Baazaoui N, Liu F, Iqbal K. Inhibition of AMD-like pathology with a neurotrophic compound in aged rats and 3xTg-AD mice. Frontiers in Aging Neuroscience. 2019;11:309. doi:10.3389/fnagi.2019.00309.
10. Wei W, Wang Y, Liu Y, Dai CL, Tung YC, Liu F, Iqbal K. Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice. Alzheimer’s Research & Therapy. 2020;12:102. doi:10.1186/s13195-020-00666-7. PMID:32854771.
11. Wei W, Liu Y, Dai CL, Baazaoui N, Tung YC, Liu F, Iqbal K. Neurotrophic treatment initiated during early postnatal development prevents Alzheimer-like behavior and synaptic dysfunction. Journal of Alzheimer’s Disease. 2021;82(2):631–646. doi:10.3233/JAD-201599. PMID:34057082.
12. Mottolese N, Loi M, Trazzi S, et al. Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. Journal of Neurodevelopmental Disorders. 2024;16:65. doi:10.1186/s11689-024-09583-4. PMID:39592934.

Research-use-only notice

Research Use Only. This material is provided for laboratory and educational research purposes only. It is not intended for human or veterinary use, diagnosis, treatment, cure, mitigation, or prevention of any disease. This article summarizes published research and does not constitute medical advice, a dosing recommendation, or a claim of safety or efficacy. P021 remains a preclinical research compound; published animal and cellular findings cannot be assumed to apply to humans.